Literature DB >> 24681128

Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Robert J Fontana1, Paul H Hayashi2, Jiezhun Gu3, K Rajender Reddy4, Huiman Barnhart3, Paul B Watkins2, Jose Serrano5, William M Lee6, Naga Chalasani7, Andrew Stolz8, Timothy Davern9, Jayant A Talwakar10.   

Abstract

BACKGROUND & AIMS: Little is known about the incidence of drug-induced liver injury (DILI) and risk factors for adverse outcomes. We evaluated short-term outcomes of a large cohort of patients with DILI enrolled in an ongoing multicenter prospective study.
METHODS: Data were collected from 660 adults with definite, highly likely, or probable DILI. Regression methods were used to identify risk factors for early liver-related death or liver transplantation and chronic liver injury.
RESULTS: Patients' median age was 51.4 years; 59.5% were female and 59.1% required hospitalization. Within 6 months of DILI onset, 30 patients received liver transplants (4.5%; 95% confidence interval [CI], 3.0%-6.1%) and 32 died (5%; 95% CI, 3.2%-6.5%); 53% of the deaths were liver related. Asian race, absence of itching, lung disease, low serum albumin levels, low platelet counts, and high serum levels of alanine aminotransferase and total bilirubin at presentation were independent risk factors for reduced times to liver-related death or liver transplantation (C-statistic = 0.87). At 6 months after DILI onset, 18.9% of the 598 evaluable subjects had persistent liver damage. African-American race, higher serum levels of alkaline phosphatase, and prior heart disease or malignancy requiring treatment were independent risk factors for chronic DILI (C-statistic = 0.71).
CONCLUSIONS: Nearly 1 in 10 patients die or undergo liver transplantation within 6 months of DILI onset and nearly 1 in 5 of the remaining patients have evidence of persistent liver injury at 6 months. The profile of liver injury at presentation, initial severity, patient's race, and medical comorbidities are important determinants of the likelihood of death/transplantation or persistent liver injury within 6 months.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute Liver Failure; Causality; Hepatotoxicity; Transplantation

Mesh:

Year:  2014        PMID: 24681128      PMCID: PMC4285559          DOI: 10.1053/j.gastro.2014.03.045

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  22 in total

1.  Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.

Authors:  George Ostapowicz; Robert J Fontana; Frank V Schiødt; Anne Larson; Timothy J Davern; Steven H B Han; Timothy M McCashland; A Obaid Shakil; J Eileen Hay; Linda Hynan; Jeffrey S Crippin; Andres T Blei; Grace Samuel; Joan Reisch; William M Lee
Journal:  Ann Intern Med       Date:  2002-12-17       Impact factor: 25.391

2.  The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected].

Authors:  Mark V Galan; Jeffrey A Potts; Ann L Silverman; Stuart C Gordon
Journal:  J Clin Gastroenterol       Date:  2005-01       Impact factor: 3.062

3.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.

Authors:  Raúl J Andrade; M Isabel Lucena; M Carmen Fernández; Gloria Pelaez; Ketevan Pachkoria; Elena García-Ruiz; Beatriz García-Muñoz; Rocio González-Grande; Angeles Pizarro; José Antonio Durán; Manuel Jiménez; Luis Rodrigo; Manuel Romero-Gomez; José María Navarro; Ramón Planas; Joan Costa; Africa Borras; Aina Soler; Javier Salmerón; Rafael Martin-Vivaldi
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

4.  The natural history of histologically proved drug induced liver disease.

Authors:  P G Aithal; C P Day
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 5.  Hypersensitivity syndrome to antiepileptic drugs: a review including new anticonvulsants.

Authors:  H M Hamer; H H Morris
Journal:  Cleve Clin J Med       Date:  1999-04       Impact factor: 2.321

6.  Comparison of two clinical scales for causality assessment in hepatotoxicity.

Authors:  M I Lucena; R Camargo; R J Andrade; C J Perez-Sanchez; F Sanchez De La Cuesta
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

7.  Outcome and prognostic markers in severe drug-induced liver disease.

Authors:  Einar Björnsson; Rolf Olsson
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

8.  Incidence of drug-induced hepatic injuries: a French population-based study.

Authors:  Catherine Sgro; François Clinard; Kader Ouazir; Henry Chanay; Christian Allard; Christian Guilleminet; Claude Lenoir; Alain Lemoine; Patrick Hillon
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

9.  Liver transplantation for acute liver failure from drug induced liver injury in the United States.

Authors:  Mark W Russo; Joseph A Galanko; Roshan Shrestha; Michael W Fried; Paul Watkins
Journal:  Liver Transpl       Date:  2004-08       Impact factor: 5.799

10.  Nonalcoholic fatty liver disease in patients with type 2 diabetes.

Authors:  Zobair M Younossi; Terry Gramlich; Christi A Matteoni; Navdeep Boparai; Arthur J McCullough
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

View more
  68 in total

Review 1.  Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy.

Authors:  Shannan R Tujios; William M Lee
Journal:  Liver Int       Date:  2017-09-18       Impact factor: 5.828

2.  A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury.

Authors:  Lauren Heidemann; James Law; Robert J Fontana
Journal:  Dig Dis Sci       Date:  2015-11-23       Impact factor: 3.199

3.  The Natural History of Severe Acute Liver Injury.

Authors:  David G Koch; J L Speiser; V Durkalski; R J Fontana; T Davern; B McGuire; R T Stravitz; A M Larson; I Liou; O Fix; M L Schilsky; T McCashland; J E Hay; N Murray; O S Shaikh; D Ganger; A Zaman; S B Han; R T Chung; R S Brown; S Munoz; K R Reddy; L Rossaro; R Satyanarayana; A J Hanje; J Olson; R M Subramanian; C Karvellas; B Hameed; A H Sherker; W M Lee; A Reuben
Journal:  Am J Gastroenterol       Date:  2017-04-25       Impact factor: 10.864

4.  Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury.

Authors:  Jawad Ahmad; K Rajender Reddy; Hans L Tillmann; Paul H Hayashi; Naga Chalasani; Robert J Fontana; Victor J Navarro; Andrew Stolz; Huiman Barnhart; Gavin A Cloherty; Jay H Hoofnagle
Journal:  Dig Dis Sci       Date:  2019-03-29       Impact factor: 3.199

5.  The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.

Authors:  Robert John Fontana; Elizabeth Theresa Cirulli; Jiezhun Gu; David Kleiner; David Ostrov; Elizabeth Phillips; Ryan Schutte; Huiman Barnhart; Naga Chalasani; Paul Brent Watkins; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

6.  Mortality associated with drug-induced liver injury (DILI).

Authors:  Einar S Björnsson; Helgi K Björnsson
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-19

Review 7.  Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity.

Authors:  Jawad Ahmad; Joseph A Odin
Journal:  Clin Liver Dis       Date:  2016-10-14       Impact factor: 6.126

8.  Utility of a Computerized ICD-10 Algorithm to Identify Idiosyncratic Drug-Induced Liver Injury Cases in the Electronic Medical Record.

Authors:  Amoah Yeboah-Korang; Jeremy Louissaint; Irene Tsung; Sharmila Prabhu; Robert J Fontana
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

9.  Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

Authors:  Naga Chalasani; Herbert L Bonkovsky; Robert Fontana; William Lee; Andrew Stolz; Jayant Talwalkar; K Rajendar Reddy; Paul B Watkins; Victor Navarro; Huiman Barnhart; Jiezhun Gu; Jose Serrano
Journal:  Gastroenterology       Date:  2015-03-06       Impact factor: 22.682

10.  Hepatotoxicity associated with weight loss or sports dietary supplements, including OxyELITE Pro™ - United States, 2013.

Authors:  Kevin Chatham-Stephens; Ethel Taylor; Arthur Chang; Amy Peterson; Johnni Daniel; Colleen Martin; Patricia Deuster; Rebecca Noe; Stephanie Kieszak; Josh Schier; Karl Klontz; Lauren Lewis
Journal:  Drug Test Anal       Date:  2016-08-04       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.